Metsera Inc. (MTSR)
NASDAQ: MTSR
· Real-Time Price · USD
53.00
-0.58 (-1.08%)
At close: Sep 23, 2025, 3:59 PM
-1.08% (1D)
Bid | 52.87 |
Market Cap | 5.57B |
Revenue (ttm) | n/a |
Net Income (ttm) | -307.82M |
EPS (ttm) | -2.94 |
PE Ratio (ttm) | -18.03 |
Forward PE | -15.09 |
Analyst | Buy |
Dividends | n/a |
Ask | 53 |
Volume | 6,395,470 |
Avg. Volume (20D) | 1,737,319 |
Open | 53.05 |
Previous Close | 53.58 |
Day's Range | 52.63 - 53.45 |
52-Week Range | 12.30 - 54.47 |
Beta | 0.75 |
Ex-Dividend Date | n/a |
About MTSR
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol MTSR
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for MTSR stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts2 days ago
+60.8%
Metsera shares are trading higher on reports that ...
Unlock content with
Pro Subscription
1 month ago
-5.73%
Metsera shares are trading lower after the company reported worse-than-expected Q2 EPS results.

20 hours ago · proactiveinvestors.co.uk
Pfizer's Metsera buy raises competitive heat for Novo NordiskUBS has warned that Pfizer Inc's (NYSE:PFE, ETR:PFE) $7.3 billion acquisition of Metsera will sharpen competition for Novo Nordisk (NYSE:NVO) in the fast-growing obesity drug market, particularly towa...

1 day ago · proactiveinvestors.com
Pfizer acquires Metsera in $7.3B deal to boost obesity drug pipelinePfizer Inc (NYSE:PFE, ETR:PFE) on Monday announced that it will acquire Metsera, Inc (NASDAQ: MTSR), a weight-loss drug developer, in a deal valued at up to $7.3 billion, or $47.50 per share in cash. ...